The Influence of Routes of Administration on 3-chloromethcathinone Urinary Biomarkers Disposition: Preliminary In Vivo Study of Unknown Metabolites Profiling on Healthy Volunteers
Por:
Di Trana, A, La Maida, N, Graziano, S, Pichini, S, Hladun, O, Poyatos, L, Ventura, M, Papaseit, E, Farré, M and Perez-Maña, C
Publicada:
8 ene 2026
Resumen:
In 2024, 3-Chloromethcathinone (3-CMC) accounted for over 63% of all New Psychoactive Substances seized in Europe, yet its human pharmacology remains poorly understood. This observational, uncontrolled, naturalistic study involved 16 regular psychostimulant users to evaluate and compare 3-CMC metabolism, and distribution in urine and oral fluid (OF) following oral and intranasal administration. Two groups, each consisting of 8 participants (6 males, 2 females) self-administered 3-CMC in two separate sessions: 100-150 mg orally and 60-80 mg intranasally. Urine was collected in two pooled intervals (0-2 h and 2-5 h). Samples were analyzed via four untargeted HPLC-HRMS/MS methods in full MS and ddMS2 to characterize the unknown metabolites supported by Compound Discoverer (TM) software with an established workflow. The data were grouped into four groups concerning the route of administration and the time intervals and the average area were statistically compared with a one-way ANOVA. The parent drug was detected in all the samples at different levels. In total, nine metabolites were observed, of those 4 were phase I and 5 phase II metabolites. Considering the route of administration, distinct metabolic patterns emerged: three metabolites, including two N-acetylated forms and a carboxylated metabolite, were found only after oral intake, suggesting N-acetylation occurs primarily via this route. In contrast, beta-OH-3-CMC accumulated more after intranasal use. Furthermore, 3-CMC N- glucuronidation was hypothesized for the first time. These findings indicate that the administration route significantly influences 3-CMC metabolism, highlighting the need for tailored forensic and toxicological assessments.
Filiaciones:
Di Trana, A:
Italian Natl Inst Hlth, Natl Ctr Addict & Doping, Viale Regina Elena 299, I-00161 Rome, Italy
La Maida, N:
Italian Natl Inst Hlth, Natl Ctr Addict & Doping, Viale Regina Elena 299, I-00161 Rome, Italy
Graziano, S:
Italian Natl Inst Hlth, Natl Ctr Addict & Doping, Viale Regina Elena 299, I-00161 Rome, Italy
Pichini, S:
Italian Natl Inst Hlth, Natl Ctr Addict & Doping, Viale Regina Elena 299, I-00161 Rome, Italy
Hladun, O:
Hosp Univ Germans Trias i Pujol, Dept Clin Pharmacol, Badalona, Spain
IGTP, Inst Recerca Germans Trias I Pujol HUGTP, Badalona, Spain
Univ Autonoma Barcelona, Dept Pharmacol, Cerdanyola Del Valles, Spain
:
Hosp Univ Germans Trias i Pujol, Dept Clin Pharmacol, Badalona, Spain
IGTP, Inst Recerca Germans Trias I Pujol HUGTP, Badalona, Spain
Ventura, M:
Assoc Benestar & Desenvolupament, Energy Control, Barcelona, Spain
:
Hosp Univ Germans Trias i Pujol, Dept Clin Pharmacol, Badalona, Spain
IGTP, Inst Recerca Germans Trias I Pujol HUGTP, Badalona, Spain
Univ Autonoma Barcelona, Dept Pharmacol, Cerdanyola Del Valles, Spain
Hosp Mar Med Res Inst IMIM, Addict Res Grp, Barcelona, Spain
Farré, M:
Hosp Univ Germans Trias i Pujol, Dept Clin Pharmacol, Badalona, Spain
IGTP, Inst Recerca Germans Trias I Pujol HUGTP, Badalona, Spain
Univ Autonoma Barcelona, Dept Pharmacol, Cerdanyola Del Valles, Spain
:
Hosp Univ Germans Trias i Pujol, Dept Clin Pharmacol, Badalona, Spain
IGTP, Inst Recerca Germans Trias I Pujol HUGTP, Badalona, Spain
Univ Autonoma Barcelona, Dept Pharmacol, Cerdanyola Del Valles, Spain
|